Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2005 1
2006 1
2007 2
2008 3
2009 1
2010 1
2013 1
2014 5
2015 5
2017 2
2019 2
2020 3
2021 3
2022 5
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors.
Umiker B, Hashambhoy-Ramsay Y, Smith J, Rahman T, Mueller A, Davidson R, Meyer C, Patankar G, Alam MM, Jaffe S, Krukenberg K, Goodman A, Spaulding V, Priess M, Dhaneshwar A, Wong M, Diiorio A, O'Malley K, McGrath L, Willer M, Pepper L, Gostissa M, Kis-Toth K, Wiederschain D, Cohen H, Shaffer DR. Umiker B, et al. Among authors: wiederschain d. Mol Cancer Ther. 2023 Apr 3;22(4):471-484. doi: 10.1158/1535-7163.MCT-22-0351. Mol Cancer Ther. 2023. PMID: 36780212
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody.
Weaver JD, Stack EC, Buggé JA, Hu C, McGrath L, Mueller A, Wong M, Klebanov B, Rahman T, Kaufman R, Fregeau C, Spaulding V, Priess M, Legendre K, Jaffe S, Upadhyay D, Singh A, Xu CA, Krukenberg K, Zhang Y, Ezzyat Y, Saddier Axe D, Kuhne MR, Meehl MA, Shaffer DR, Weist BM, Wiederschain D, Depis F, Gostissa M. Weaver JD, et al. Among authors: wiederschain d. Oncoimmunology. 2022 Nov 4;11(1):2141007. doi: 10.1080/2162402X.2022.2141007. eCollection 2022. Oncoimmunology. 2022. PMID: 36352891 Free PMC article.
BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression.
Mandel I, Haves Ziv D, Goldshtein I, Peretz T, Alishekevitz D, Fridman Dror A, Hakim M, Hashmueli S, Friedman I, Sapir Y, Greco R, Qu H, Nestle F, Wiederschain D, Pao L, Sharma S, Ben Moshe T. Mandel I, et al. Among authors: wiederschain d. J Immunother Cancer. 2022 Sep;10(9):e004859. doi: 10.1136/jitc-2022-004859. J Immunother Cancer. 2022. PMID: 36096532 Free PMC article.
Publisher Correction: A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells.
Seung E, Xing Z, Wu L, Rao E, Cortez-Retamozo V, Ospina B, Chen L, Beil C, Song Z, Zhang B, Levit M, Deng G, Hebert A, Kirby P, Li A, Poulton EJ, Vicente R, Garrigou A, Piepenhagen P, Ulinski G, Sanicola-Nadel M, Bangari DS, Qiu H, Pao L, Wiederschain D, Wei R, Yang ZY, Nabel GJ. Seung E, et al. Among authors: wiederschain d. Nature. 2022 Apr;604(7905):E13. doi: 10.1038/s41586-022-04652-x. Nature. 2022. PMID: 35332336 No abstract available.
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
Kassem S, Diallo BK, El-Murr N, Carrié N, Tang A, Fournier A, Bonnevaux H, Nicolazzi C, Cuisinier M, Arnould I, Sidhu SS, Corre J, Avet-Loiseau H, Teillaud JL, van de Velde H, Wiederschain D, Chiron M, Martinet L, Virone-Oddos A. Kassem S, et al. Among authors: wiederschain d. Blood. 2022 Feb 24;139(8):1160-1176. doi: 10.1182/blood.2021012448. Blood. 2022. PMID: 35201323 Free article.
A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells.
Seung E, Xing Z, Wu L, Rao E, Cortez-Retamozo V, Ospina B, Chen L, Beil C, Song Z, Zhang B, Levit M, Deng G, Hebert A, Kirby P, Li A, Poulton EJ, Vicente R, Garrigou A, Piepenhagen P, Ulinski G, Sanicola-Nadel M, Bangari DS, Qiu H, Pao L, Wiederschain D, Wei R, Yang ZY, Nabel GJ. Seung E, et al. Among authors: wiederschain d. Nature. 2022 Mar;603(7900):328-334. doi: 10.1038/s41586-022-04439-0. Epub 2022 Feb 23. Nature. 2022. PMID: 35197632
Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models.
Hotz C, Wagenaar TR, Gieseke F, Bangari DS, Callahan M, Cao H, Diekmann J, Diken M, Grunwitz C, Hebert A, Hsu K, Bernardo M, Karikó K, Kreiter S, Kuhn AN, Levit M, Malkova N, Masciari S, Pollard J, Qu H, Ryan S, Selmi A, Schlereth J, Singh K, Sun F, Tillmann B, Tolstykh T, Weber W, Wicke L, Witzel S, Yu Q, Zhang YA, Zheng G, Lager J, Nabel GJ, Sahin U, Wiederschain D. Hotz C, et al. Among authors: wiederschain d. Sci Transl Med. 2021 Sep 8;13(610):eabc7804. doi: 10.1126/scitranslmed.abc7804. Epub 2021 Sep 8. Sci Transl Med. 2021. PMID: 34516826
Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.
Bonnevaux H, Guerif S, Albrecht J, Jouannot E, De Gallier T, Beil C, Lange C, Leuschner WD, Schneider M, Lemoine C, Caron A, Amara C, Barrière C, Siavellis J, Bardet V, Luna E, Agrawal P, Drake DR, Rao E, Wonerow P, Carrez C, Blanc V, Hsu K, Wiederschain D, Fraenkel PG, Virone-Oddos A. Bonnevaux H, et al. Among authors: wiederschain d. Oncoimmunology. 2021 Aug 31;10(1):1945803. doi: 10.1080/2162402X.2021.1945803. eCollection 2021. Oncoimmunology. 2021. PMID: 34484869 Free PMC article.
An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy.
Bernardo M, Tolstykh T, Zhang YA, Bangari DS, Cao H, Heyl KA, Lee JS, Malkova NV, Malley K, Marquez E, Pollard J, Qu H, Roberts E, Ryan S, Singh K, Sun F, Wang E, Bahjat K, Wiederschain D, Wagenaar TR. Bernardo M, et al. Among authors: wiederschain d. Oncoimmunology. 2021 Mar 16;10(1):1881268. doi: 10.1080/2162402X.2021.1881268. Oncoimmunology. 2021. PMID: 33796402 Free PMC article.
39 results